Analyzing Humana's Stock Performance

By Emilio Sanchez • Wednesday, January 17 15:16 • Permanent Link

Humana logged a 2.4% change during today's afternoon session, and is now trading at a price of $449.22 per share. The S&P 500 index moved -1.0%. HUM's trading volume is 1,823,430 compared to the stock's average volume of 1,441,606.

Humana trades -22.85% away from its average analyst target price of $582.28 per share. The 18 analysts following the stock have set target prices ranging from $531.0 to $640.0, and on average have given Humana a rating of buy.

Anyone interested in buying HUM should be aware of the facts below:

Humana's current price is 64.8% above its Graham number of $272.6, which implies that at its current valuation it does not offer a margin of safety
Humana has moved -9.5% over the last year, and the S&P 500 logged a change of 21.3%
Based on its trailing earnings per share of 24.18, Humana has a trailing 12 month Price to Earnings (P/E) ratio of 18.6 while the S&P 500 average is 15.97
HUM has a forward P/E ratio of 14.3 based on its forward 12 month price to earnings (EPS) of $31.45 per share
The company has a price to earnings growth (PEG) ratio of 1.14 — a number near or below 1 signifying that Humana is fairly valued compared to its estimated growth potential
Its Price to Book (P/B) ratio is 3.26 compared to its sector average of 4.08
Humana Inc., together with its subsidiaries, operates as a health and well-being company in the United States.
Based in Louisville, the company has 67,100 full time employees and a market cap of $55.3 Billion. Humana currently returns an annual dividend yield of 0.8%.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.